A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
MEDIZIN.NEWZS.de – Quantum Related Diseases Research Group (QRDRG)
Forschungsgruppe Quanteneffekte bei Krankheiten (qrdrg.xonl.de)